Tetrahydroquinoline derivative and medicinal use thereof

US2024116903A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2024116903-A1
Application numberUS-202118268667-A
CountryUS
Kind codeA1
Filing dateDec 24, 2021
Priority dateDec 25, 2020
Publication dateApr 11, 2024
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A compound has a tetra-hydroquinoline skeleton, the compound having inhibitory action against ferroptosis, and exerting therapeutic or preventive effect on diseases, disorders or syndromes related to ferroptosis inhibition, such as multiple sclerosis. This disclosure provides a tetrahydroquinoline derivative represented by the following formula or a pharmaceutically acceptable salt thereof:

First claim

Opening claim text (preview).

1 - 15 . (canceled) 16 . A tetrahydroquinoline derivative represented by general formula (I) below or a pharmaceutically acceptable salt thereof, wherein R 1x is hydrogen, phenyl, or 5- or 6-membered heteroaryl selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, and pyridyl; R 1y is hydrogen, 4-hydroxymethylphenyl, 4-aminocarbonylphenyl, 4-acetamidophenyl, 4-aminosulfonylphenyl, or 4-methylsulfonylphenyl (provided that R 1y is a substituent other than hydrogen when R 1x is hydrogen, or that R 1y is hydrogen when R 1x is a substituent other than hydrogen); for a combination of R 2 , R 4 , and R 5 , all of R 2 , R 4 , and R 5 represent hydrogen; otherwise, one of R 2 and R 4 is fluorine, chlorine, methoxy, or methyl in which one hydrogen atom is optionally replaced by a hydroxy group, and both the other and R 5 represent hydrogen; otherwise, both R 2 and R 4 represent hydrogen, and R 5 is fluorine or chlorine; R 3 is hydrogen, halogen, C 1 -C 3 alkyl in which any one to three hydrogen atoms are each independently optionally replaced by a hydroxy group(s) or a fluorine atom(s), 3-hydroxyoxetan-3-yl, hydroxy, C 1 -C 3 alkoxy in which any one to three hydrogen atoms are optionally replaced by a fluorine atom(s), methoxycarbonyl, —NR 9 R 10 , —CH 2 NR 11 R 12 , or —CH 2 CONR 13 R 14 ; R v is hydrogen; and R w is hydrogen; wherein, when R 1x is phenyl (any one hydrogen atom in the phenyl group is optionally replaced by one substituent selected from the group consisting of halogen, C 1 -C 3 alkyl in which any one to three hydrogen atoms are optionally replaced by a fluorine atom(s), C 1 -C 3 alkoxy in which any one to three hydrogen atoms are optionally replaced by a fluorine atom(s), cyano, methoxycarbonyl, and —NHCOR 8 , provided that m-cyanophenyl and p-(trifluoromethoxy)phenyl are excluded) or 5- or 6-membered heteroaryl (any one hydrogen atom in the 5- or 6-membered heteroaryl is optionally replaced by a C 1 -C 3 alkyl or C 1 -C 3 alkoxy group, provided that 1-methyl-1H-pyrazol-4-yl and 6-methoxypyridin-3-yl are excluded), R 3 is C 1 -C 3 alkyl in which any one to three hydrogen atoms are replaced by a fluorine atom(s), C 1 -C 3 alkyl in which any one hydrogen atom is replaced by a hydroxy group, ethyl, propyl, isopropyl, 3-hydroxyoxetan-3-yl, methoxy in which any one to three hydrogen atoms are replaced by a fluorine atom(s), methoxycarbonyl, —NR 9 R 10 , —CH 2 NR 11 R 12 , or —CH 2 CONR 13 R 14 (wherein, when both R 2 and R 4 represent hydrogen and R 5 is fluorine or chlorine, R 3 is optionally hydrogen or fluorine, or when both R 2 and R 5 represent hydrogen and R 4 is fluorine or chlorine, R 3 is optionally fluorine, or when R 2 is methyl in which one hydrogen atom is optionally replaced by a hydroxy group, and both R 4 and R 5 represent hydrogen, R 3 is optionally hydrogen); R 8 is hydrogen or C 1 -C 3 alkyl; R 9 is hydrogen; R 10 is hydrogen, —COR 15 , or C 1 -C 3 alkylsulfonyl, or R 9 and R 10 together represent —(CH 2 ) n —; n is 4 or 5; R 11 and R 12 together represent —(CH 2 ) m —; m is 4 or 5, wherein any one of the methylene groups is optionally replaced by an oxygen atom; R 13 is hydrogen or methyl; R 14 is hydrogen, methyl, ethyl, isopropyl, tert-butyl, 2-hydroxyethyl, C 3 or C 4 cycloalkyl in which any one carbon atom is optionally replaced by an oxygen atom, or methyl which is substituted with a C 3 or C 4 cycloalkyl group in which any one carbon atom is optionally replaced by a nitrogen or oxygen atom, or R 13 and R 14 , together with the nitrogen atom which is bound to R 13 and R 14 , optionally form a pyrrolidine ring, a piperidine ring, a piperazine ring, a morpholine ring, a piperazinone ring, or an azetidine ring in which any two hydrogen atoms are optionally replaced by a methyl group(s) and/or a fluorine atom(s) or in which any one hydrogen atom is optionally replaced by a hydroxy or methoxy group; R 15 is C 1 -C 5 alkyl, C 1 -C 5 alkoxy, or —NHR 16 ; and R 16 is hydrogen or C 1 -C 5 alkyl; or when R 1x is hydrogen, phenyl (any one hydrogen atom in the phenyl group is replaced by a C 1 -C 3 alkyl in which any one hydrogen atom is replaced by a hydroxy group, —CONR 6 R 7 , aminosulfonyl, methylsulfonylamino, aminosulfonylamino, or C 1 -C 3 alkylsulfonyl group; otherwise, the hydrogen atom at the meta-position of the phenyl group is replaced by a cyano group; otherwise, the hydrogen atom at the para-position of the phenyl group is replaced by a trifluoromethoxy group), 1-methyl-1H-pyrazol-4-yl, or 6-methoxypyridin-3-yl, or when R 1x is a fused ring group formed by fusing of a phenyl group and one ring selected from the group consisting of pyrrolidin-2-one, piperidin-2-one, and 1,3-dioxolane (wherein any one hydrogen atom in the fused ring group is optionally replaced by a methyl group), R 3 is hydrogen, fluorine, chlorine, bromine, C 1 -C 3 alkyl in which any one to three hydrogen atoms are optionally replaced by a fluorine atom(s) or any one hydrogen atom is optionally replaced by a hydroxy group, 3-hydroxyoxetan-3-yl, hydroxy, methoxy in which any one to three hydrogen atoms are optionally replaced by a fluorine atom(s), methoxycarbonyl, —NR 9 R 10 , —CH 2 NR 11 R 12 , or —CH 2 CONR 13 R 14 ; R 6 and R 7 each independently represent hydrogen or C 1 -C 3 alkyl, or R 6 and R 7 , together with the nitrogen atom which is bound to R 6 and R 7 , optionally form a piperidine ring, a morpholine ring, a piperazine ring, or an N-methylpiperazine ring; R 9 is hydrogen; R 10 is hydrogen, —COR 15 , or C 1 -C 3 alkylsulfonyl, or R 9 and R 10 together represent —(CH 2 ) n —; n is 4 or 5; R 11 and R 12 together represent —(CH 2 ) m —; m is 4 or 5, wherein any one of the methylene groups is optionally replaced by an oxygen atom; R 13 is hydrogen or methyl; R 14 is hydrogen, methyl, ethyl, isopropyl, tert-butyl, 2-hydroxyethyl, C 3 or C 4 cycloalkyl in which any one carbon atom is optionally replaced by an oxygen atom, or methyl which is substituted with a C 3 or C 4 cycloalkyl group in which any one carbon atom is optionally replaced by a nitrogen or oxygen atom, or R 13 and R 14 , together with the nitrogen atom which is bound to R 13 and R 14 , optionally form a pyrrolidine ring, a piperidine ring, a piperazine ring, a morpholine ring, a piperazinone ring, or an azetidine ring in which any two hydrogen atoms are optionally replaced by a methyl group(s) and/or a fluorine atom(s) or in which any one hydrogen atom is optionally replaced by a hydroxy or methoxy group; R 15 is C 1 -C 5 alkyl, C 1 -C 5 alkoxy, or —NHR 16 ; and R 16 is hydrogen or C 1 -C 5 alkyl (provided that methyl 2-(4-methoxyphenyl)-1,2,3,4-tetrahydroquinoline-6-carboxylate and 2-(benzo[d][1,3]dioxol-5-yl)-1,2,3,4-tetrahydroquinoline are excluded). 17 . The tetrahydroquinoline derivative or a pharmaceutically acceptable salt thereof according to claim 16 , wherein R 1x is phenyl or 5- or 6-membered heteroaryl selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, and pyridyl; R 1y is hydrogen; for a combination of R 2 , R 4 , and R 5 , all of R 2 , R 4 , and R 5 represent hydrogen; otherwise, one of R 2 and R 4 is fluorine, chlorine, methoxy, or methyl in which one hydrogen atom is optionally replaced by a hydroxy group, and both the other and R 5 represent hydrogen; otherwise, both R 2 and R 4 represent hydrogen, and R 5 is fluorine or chlorine; R v is hydrogen; and R w is hydrogen; wherein, when R 1x is phenyl (any one hydrogen atom in the phenyl group is optionally replaced by

Assignees

Inventors

Classifications

  • attached in position 4 · CPC title

  • Radicals substituted by oxygen atoms · CPC title

  • C07D405/04Primary

    directly linked by a ring-member-to-ring-member bond · CPC title

  • directly linked by a ring-member-to-ring-member bond · CPC title

  • directly linked by a ring-member-to-ring-member bond · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2024116903A1 cover?
A compound has a tetra-hydroquinoline skeleton, the compound having inhibitory action against ferroptosis, and exerting therapeutic or preventive effect on diseases, disorders or syndromes related to ferroptosis inhibition, such as multiple sclerosis. This disclosure provides a tetrahydroquinoline derivative represented by the following formula or a pharmaceutically acceptable salt thereof:
Who is the assignee on this patent?
Toray Industries
What technology area does this patent fall under?
Primary CPC classification C07D405/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Apr 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).